Combination Of Liposomal Doxorubicine Plus Gemcitabine In Heavily Pretreated Metastatic Breast Cancer Patients: A Single Center Experience.

e12015 Background: The combination of Pegylated Liposomal Doxorubicin (PDL) plus Gemcitabine (GEM) has been previously investigated in the treatment of recurrent metastatic breast cancer (RMBC) patients. PLD is a new formulation of doxorubicin with a prolonged circulation time and a better tissue distribution. GEM is a nucleoside analogue with non-overlapping toxicity as compared to PLD. The aim of our study was to assess the efficacy, toxicity and long-term outcome. Methods: Patients (pts) with RMBC were retrospectively analyzed. Chemotherapy consisted of PDL 30mg/m2 day 1 and GEM 800mg/m2 day 1 and 8, on a three-week schedule. Cardiac function was evaluated before initiation. Radiological response was graded according to RECIST criteria v1.1. Toxicity was scored according to NCI-CTC v4.0. The regimen was administered until progression or severe toxicity. Results: From January 2001 to January 2014, 131 pts [(median age 59 (range 28-84); ECOG 0 (36%); 1 (56%); 2 (8%)] were included. Immunohistopathogical ...